Cellular Biomedicine (CBMG) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:CBMG

19.75
0 (0%)
Last: Feb 19, 2021, 08:00 PM

CBMG Key Statistics, Chart & Performance

Key Statistics
Market Cap384.69M
Revenue(TTM)323.00K
Net Income(TTM)-54.81M
Shares19.48M
Float17.92M
52 Week High19.76
52 Week Low11.48
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.82
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
CBMG short term performance overview.The bars show the price performance of CBMG in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 2 4 6 8

CBMG long term performance overview.The bars show the price performance of CBMG in the last 1, 2 and 3 years. 1 year 2 years 3 years 5 10 15

The current stock price of CBMG is 19.75 null. In the past month the price increased by 9.72%. In the past year, price increased by 18.41%.

Cellular Biomedicine / CBMG Daily stock chart

CBMG Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to CBMG. When comparing the yearly performance of all stocks, CBMG turns out to be only a medium performer in the overall market: it outperformed 49.81% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CBMG Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to CBMG. CBMG may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CBMG Financial Highlights

Over the last trailing twelve months CBMG reported a non-GAAP Earnings per Share(EPS) of -2.82. The EPS decreased by -17.01% compared to the year before.


Industry RankSector Rank
PM (TTM) -16967.89%
ROA -58.88%
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-7.32%
Sales Q2Q%N/A
EPS 1Y (TTM)-17.01%
Revenue 1Y (TTM)330.67%

CBMG Forecast & Estimates


Analysts
Analysts60
Price TargetN/A
EPS Next Y-6.46%
Revenue Next YearN/A

CBMG Ownership

Ownership
Inst Owners0.02%
Ins Owners21.1%
Short Float %N/A
Short RatioN/A

About CBMG

Company Profile

Cellular Biomedicine Group Inc. is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. The Company offers developmental stem cell, progenitor cell, and immune cell projects. It is developing treatments utilizing proprietary cell technologies for the treatment of a range of cancers; joint disease and central nervous system diseases. Cellular Biomedicine Group Inc. is headquartered in Palo Alto, California.

Company Info

Cellular Biomedicine

1345 AVENUE OF AMERICAS 15TH FLOOR

NEW YORK NY 10105

CEO: Bizuo (Tony) Liu

Phone: 347-905-5663

Cellular Biomedicine / CBMG FAQ

What does Cellular Biomedicine do?

Cellular Biomedicine Group Inc. is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. The Company offers developmental stem cell, progenitor cell, and immune cell projects. It is developing treatments utilizing proprietary cell technologies for the treatment of a range of cancers; joint disease and central nervous system diseases. Cellular Biomedicine Group Inc. is headquartered in Palo Alto, California.


Can you provide the latest stock price for Cellular Biomedicine?

The current stock price of CBMG is 19.75 null.


What is the dividend status of Cellular Biomedicine?

CBMG does not pay a dividend.


What is the ChartMill technical and fundamental rating of CBMG stock?

CBMG has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Who owns Cellular Biomedicine?

You can find the ownership structure of Cellular Biomedicine (CBMG) on the Ownership tab.